MUNDELEIN, Ill., Jan. 13 /PRNewswire/ -- Bio-logic Systems Corp.
(Nasdaq: BLSC), a designer and marketer of computerized medical electro-
diagnostic equipment, today announced that it has been awarded a contract by
Boston Children's Hospital worth approximately $1.4 million.  The contract
encompasses the purchase of Bio-logic's comprehensive family of
neurodiagnostic systems including long-term epilepsy monitoring, clinical EEG,
ambulatory EEG, polysomnography, and intraoperative evoked potential
monitoring as well as reader stations in multiple locations.
    Under the contract, Bio-logic will provide a state-of-the-art, integrated
clinical neurophysiology laboratory.  The clinical neurophysiology laboratory
installation combines laboratory, portable and home monitoring systems, all
networked to provide convenient access to patient records from multiple
locations in order to maximize efficiency and quality of patient care.
    Boston Children's Hospital is affiliated with Harvard Medical School and
is considered to be one of the premier pediatric neurology centers in the
country.  Bio-logic was one of several companies competing for this contract.
"Our company was founded on the idea that our systems should be expandable to
perform more than one type of test and that these tests should be upgradeable
so that our customers can cost-effectively increase their capabilities," said
Dr. Israel Raz, Bio-logic Systems Corp. marketing director. "Boston Children's
selection of Bio-logic affirms that we are taking the right approach,
utilizing the best technology."
    Bio-logic Systems Corp., headquartered in Mundelein, Ill., designs,
develops, assembles and markets computer-based electro-diagnostic systems for
use by hospitals, clinics, universities and physicians.  The systems conduct
tests that are typically used by medical practitioners to aid in the
diagnosis of certain neurological, psychiatric and sensory disorders,
psychological and learning disorders, brain disorders and tumors.
    Except for descriptions of historical facts, this release contains
forward-looking statements that involve known and unknown risks, which may
cause the company's actual results in the future to differ materially from
those currently anticipated.  These risks include, among others, fluctuations
in sales and operating results; risk associated with international operations
including monetary crisis; regulatory, competitive, and contractual risks; the
effects of economic conditions; and the availability of capital to finance
planned growth, as well as other risks detailed from time to time in the
company's filings with the Securities and Exchange Commission.

Link to this page: